<html xmlns:v="urn:schemas-microsoft-com:vml" xmlns:o="urn:schemas-microsoft-com:office:office" xmlns:w="urn:schemas-microsoft-com:office:word" xmlns:m="http://schemas.microsoft.com/office/2004/12/omml" xmlns="http://www.w3.org/TR/REC-html40"><head><meta http-equiv=Content-Type content="text/html; charset=us-ascii"><meta name=Generator content="Microsoft Word 12 (filtered medium)"><style><!--
/* Font Definitions */
@font-face
{font-family:Helvetica;
panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
{font-family:Wingdings;
panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
{font-family:"Cambria Math";
panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
{font-family:Calibri;
panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
{font-family:Verdana;
panose-1:2 11 6 4 3 5 4 4 2 4;}
/* Style Definitions */
p.MsoNormal, li.MsoNormal, div.MsoNormal
{margin:0cm;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
{mso-style-priority:99;
color:blue;
text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
{mso-style-priority:99;
color:purple;
text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
{mso-style-priority:34;
margin-top:0cm;
margin-right:0cm;
margin-bottom:0cm;
margin-left:36.0pt;
margin-bottom:.0001pt;
font-size:11.0pt;
font-family:"Calibri","sans-serif";}
span.EmailStyle18
{mso-style-type:personal;
font-family:"Verdana","sans-serif";
color:windowtext;}
span.EmailStyle19
{mso-style-type:personal-reply;
font-family:"Calibri","sans-serif";
color:#1F497D;}
.MsoChpDefault
{mso-style-type:export-only;
font-size:10.0pt;}
@page WordSection1
{size:612.0pt 792.0pt;
margin:72.0pt 72.0pt 72.0pt 72.0pt;}
div.WordSection1
{page:WordSection1;}
/* List Definitions */
@list l0
{mso-list-id:644433978;
mso-list-template-ids:588047544;}
@list l0:level1
{mso-level-number-format:bullet;
mso-level-text:\F0B7;
mso-level-tab-stop:36.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Symbol;}
@list l0:level2
{mso-level-number-format:bullet;
mso-level-text:o;
mso-level-tab-stop:72.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:"Courier New";
mso-bidi-font-family:"Times New Roman";}
@list l0:level3
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:108.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level4
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:144.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level5
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:180.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level6
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:216.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level7
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:252.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level8
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:288.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l0:level9
{mso-level-number-format:bullet;
mso-level-text:\F0A7;
mso-level-tab-stop:324.0pt;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:10.0pt;
font-family:Wingdings;}
@list l1
{mso-list-id:1607542640;
mso-list-type:hybrid;
mso-list-template-ids:-410211594 -1491704472 67698713 67698715 67698703 67698713 67698715 67698703 67698713 67698715;}
@list l1:level1
{mso-level-text:"%1\)";
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;
mso-ansi-font-size:12.0pt;
font-family:"Verdana","sans-serif";
mso-bidi-font-family:"Times New Roman";
color:windowtext;}
@list l1:level2
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;}
@list l1:level3
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l1:level4
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;}
@list l1:level5
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;}
@list l1:level6
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
@list l1:level7
{mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;}
@list l1:level8
{mso-level-number-format:alpha-lower;
mso-level-tab-stop:none;
mso-level-number-position:left;
text-indent:-18.0pt;}
@list l1:level9
{mso-level-number-format:roman-lower;
mso-level-tab-stop:none;
mso-level-number-position:right;
text-indent:-9.0pt;}
ol
{margin-bottom:0cm;}
ul
{margin-bottom:0cm;}
--></style><!--[if gte mso 9]><xml>
<o:shapedefaults v:ext="edit" spidmax="1026" />
</xml><![endif]--><!--[if gte mso 9]><xml>
<o:shapelayout v:ext="edit">
<o:idmap v:ext="edit" data="1" />
</o:shapelayout></xml><![endif]--></head><body lang=EN-CA link=blue vlink=purple><div class=WordSection1><p class=MsoNormal><span style='color:#1F497D'>Hi all:<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Below is information passed to me by one of the other PCCN groups.<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Take care,<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'>Glen<o:p></o:p></span></p><p class=MsoNormal><span style='color:#1F497D'><o:p> </o:p></span></p><p class=MsoNormal><o:p> </o:p></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><o:p> </o:p></span></p><p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l1 level1 lfo2'><![if !supportLists]><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><span style='mso-list:Ignore'>1)<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'>Prostate Cancer Canada – Annual Impact Report <span style='color:#505050'><a href="https://prostatecancer.us2.list-manage.com/track/click?u=381dca877e43c44046caa6dd1&id=8ff431c943&e=f682fa5e10"><span style='color:#00AEEF'>2017/18 Annual Impact Report</span></a><o:p></o:p></span></span></p><p class=MsoNormal><span lang=EN-US style='font-size:10.5pt;font-family:"Helvetica","sans-serif";color:#505050'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><o:p> </o:p></span></p><p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l1 level1 lfo2'><![if !supportLists]><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><span style='mso-list:Ignore'>2)<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Check out <b>video from the Us TOO <i>Prostate Cancer Pathways for Patients and Caregivers</i> educational event and webcast </b>recorded on September 29 at Englewood Health in Englewood, NJ. Presentation topics include:<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Prostate Cancer and Sexuality<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Advanced Stage Disease and Immunotherapy <o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Screening, Staging and Treatment of Localized Disease<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Integrative Medicine<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Meditation <o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Prostate Cancer 101<o:p></o:p></span></p><p class=MsoNormal style='margin-left:30.0pt;text-indent:-12.0pt;mso-list:l0 level1 lfo4'><![if !supportLists]><span lang=EN-US style='font-size:10.0pt;font-family:Symbol;color:#333333'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Men's Health<o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal style='text-indent:18.0pt'><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><a href="http://r20.rs6.net/tn.jsp?f=001om2yRMeqxQWYuJ3QScnB76N-jXT-a6ytSDHjyRP3JGOSt9BRJNtj-fAkD5q2JcfAoD-jUJZc6Br4nhrOSAQSVQ_dH95KEmzUVRhC7YPNYDTIPiehB8gEEM8cS6SLne_oZ0COjlqURjQcw0hDP9R8hfd0K-1rn-owqZVfzBS7wQA=&c=Dp5Gt1IBifkk61XWNUQsYugyvHDdNn5itEn_xdFwwuXMJDqtbE7_hw==&ch=FmCBF7akDAEmzU2thfC--P6REm8cAP0heYfvptORxW8zXtDfZoTeig==" target="_blank"><b><span style='color:#0078C1'>CLICK HERE</span></b></a> for access direct <b>links to short video segments</b> specific to each topic <b>or watch the entire presentation</b>.<o:p></o:p></span></p><p class=MsoNormal style='text-indent:18.0pt'><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal style='text-indent:18.0pt'><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoListParagraph style='text-indent:-18.0pt;mso-list:l1 level1 lfo2'><![if !supportLists]><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'><span style='mso-list:Ignore'>3)<span style='font:7.0pt "Times New Roman"'> </span></span></span><![endif]><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>From <b>psa-rising.com</b> website December 2018<o:p></o:p></span></p><p class=MsoListParagraph><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>A large new study of 87,346 patients on androgen deprivation therapy for advanced prostate cancer finds can extend life and decrease death from prostate cancer. <o:p></o:p></span></p><p class=MsoListParagraph><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Renal and Urology News sums up: "Statin use independently predicted a significant 34% decreased risk of death from any cause, 44% decreased risk of death from PCa, and 36% decreased risk of skeletal-related events, after adjusting for multiple potential confounders, including age, race, Charlson comorbidity index (CCI), Gleason score, and PSA."<o:p></o:p></span></p><p class=MsoListParagraph><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'>Study authors conclude: "The use of statins in men on ADT for castrate resistant prostate cancer [CAP] is associated with improved CSS (i.e. decreased death from the cancer] and OS [Overall Survival]. Statins are inexpensive, well-tolerated medications that offer a promising adjunct to ADT, but require further prospective studies." This study was funded by the US Department of Defense<o:p></o:p></span></p><p class=MsoListParagraph><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><a href="https://www.ncbi.nlm.nih.gov/pubmed/30528885?fbclid=IwAR0x53gXMsnCl-uOOscf4Pz_D3RF4T7-PJyiIHxSTGRDG89mFyahcDTnu8Q">https://www.ncbi.nlm.nih.gov/pubmed/30528885?fbclid=IwAR0x53gXMsnCl-uOOscf4Pz_D3RF4T7-PJyiIHxSTGRDG89mFyahcDTnu8Q</a><o:p></o:p></span></p><p class=MsoListParagraph><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoListParagraph><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal style='text-indent:18.0pt'><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal style='text-indent:18.0pt'><span lang=EN-US style='font-size:12.0pt;font-family:"Arial","sans-serif";color:#333333'><o:p> </o:p></span></p><p class=MsoNormal><span lang=EN-US style='font-size:12.0pt;font-family:"Verdana","sans-serif"'> <o:p></o:p></span></p><p class=MsoNormal><span lang=EN-US><o:p> </o:p></span></p></div></body></html>